Organon OGN

Organon & Co. is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. The company focuses on women’s health and general medicines, offering more than seventy products across contraception, fertility, biosimilars and established brands. Organon & Co. operates in over one hundred forty countries and territories and maintains six manufacturing sites located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. The company’s strategy emphasizes therapeutic areas that uniquely affect women while also expanding access to essential treatments worldwide.

Organon & Co. generates revenue primarily from the sale of its prescription pharmaceutical products. The company’s revenue streams include women’s health medicines such as contraceptive implants and rings, fertility agents and postpartum hemorrhage treatments, biosimilar therapies targeting immunology and oncology indications, and established brand medicines covering cardiovascular, respiratory, dermatology and non opioid pain management. Sales are made to drug wholesalers and retailers, hospitals, clinics, government agencies, pharmacy benefit managers and managed care organizations. Royalty income from licensing know-how and contract manufacturing fees contribute to the overall revenue mix, providing additional streams beyond product sales.

The company operates through the following segments. Each segment is managed separately to allocate resources, track performance and pursue growth initiatives aligned with the company’s long term objectives.

• The Women’s Health segment concentrates on products that address contraception, fertility and postpartum care. Key contraceptive offerings include the Nexplanon implant and the NuvaRing vaginal ring, which are distributed in numerous markets worldwide. The fertility portfolio features Follistim AQ, marketed as Puregon outside the United States, and Elonva, a sustained follicle stimulant used in assisted reproduction. The segment also provides the Jada system for managing abnormal postpartum uterine bleeding, a product that was divested to Laborie in early 2026. Additionally, Women’s Health includes Xaciato, a vaginal gel for the treatment of bacterial vaginosis. These products are prescribed by healthcare professionals and obtained through retail and hospital channels. The segment’s products are available in over ninety markets, with prescriptions written by obstetricians, gynecologists and fertility specialists, and they are reimbursed through both public and private health plans.
• The Biosimilars segment develops and commercializes biosimilar versions of reference biologics in immunology and oncology. Immunology biosimilars include Hadlima (adalimumab), Brenzys (etanercept), Renflexis (infliximab) and Tofidence (tocilizumab). Oncology biosimilars consist of Ontruzant (trastuzumab), Aybintio (bevacizumab), Bildyos and Bilprevda (both denosumab) and Poherdy (pertuzumab). The segment has secured commercialization rights in various regions through agreements with Samsung Bioepis and Henlius, allowing launches in North America, Europe, Latin America and Asia Pacific. Sales are driven by tenders with government payers and contracts with hospitals and retail pharmacies. Manufacturing of biosimilar products relies on a combination of internal facilities and third party contractors, ensuring supply reliability while maintaining compliance with regulatory standards.
• The Established Brands segment comprises mature medicines that have lost patent exclusivity but continue to generate steady cash flow. Cardiovascular products include Zetia (ezetimibe), Vytorin (ezetimibe/simvastatin), Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide). Respiratory offerings consist of Singulair (montelukast), Dulera (formoterol/fumarate), Asmanex (mometasone) and Nasonex (mometasone). Dermatology and non opioid pain management items feature Vtama (tapinarof), Diprosone (betamethasone cream), Elocon (mometasone cream), Fosamax (alendronate), Arcoxia (etoricoxib), Diprospan (betamethasone injectable) and Celestone (betamethasone injectable suspension). The segment also distributes Emgality under a collaboration with Eli Lilly for migraine prevention. These medicines are sold primarily through wholesalers, pharmacies and hospital formularies in both developed and emerging markets. Despite generic competition in many regions, the established brands portfolio continues to deliver stable earnings that support debt reduction efforts and investment in higher growth areas.

Organon & Co. holds a competitive stance in the global pharmaceutical industry by balancing a specialized women’s health franchise with a broad general medicines portfolio. The company competes with large multinational corporations such as Pfizer, Merck, Johnson & Johnson, Novartis and Roche, while also facing competition from generic manufacturers and other biosimilar developers. Organon & Co.'s advantages include its diversified revenue base, a pipeline of biosimilar candidates with approved launches in multiple jurisdictions, and a legacy brand portfolio that provides recurring income. The company’s scale in manufacturing and distribution enables it to reach patients in more than one hundred forty countries, supporting its goal of improving access to essential medicines. Organon & Co. leverages its integrated supply chain, global sales force and deep expertise in women’s health to differentiate itself from peers and sustain long term shareholder value.

The company’s customer base consists of institutional buyers and dispensing entities that procure medicines for patient use. Primary customers include drug wholesalers such as AmerisourceBergen and Cardinal Health, retail pharmacy chains, hospital systems, government health agencies and managed care organizations like UnitedHealthcare and Kaiser Permanente. Organon & Co. also works directly with health maintenance organizations and pharmacy benefit managers to secure formulary placement and reimbursement agreements. Specific commercial partnerships include a distribution agreement with Eli Lilly for the Emgality migraine therapy and contract manufacturing arrangements with Merck for various products. These relationships facilitate broad market coverage and steady demand for the company’s diversified product list. The company’s diversified channel approach reduces reliance on any single customer and enhances resilience against shifts in purchasing patterns or policy changes.